| Literature DB >> 26611787 |
Juliette Tavenier1, Anne Langkilde2, Thomas Huneck Haupt3, Jens Henrik Henriksen4, Frank Krieger Jensen5, Janne Petersen6,7, Ove Andersen8,9.
Abstract
BACKGROUND: Despite effective antiretroviral therapy (ART), HIV-infected patients exhibit systemic inflammation, early onset of age-related diseases, and features of immunosenescence. The role of inflammation in the development of age-related diseases is widely recognized. However, the role of immunosenescence is not well established. Studying immunosenescence in HIV-infection could give insight into its role in ageing processes. In this cross-sectional study, we aimed to investigate whether ART-treated HIV-infected patients exhibit immunosenescence; and whether immunosenescence is associated with age-related processes of inflammation, metabolism, adipose tissue, and muscle. T cell immunosenescence and exhaustion were assessed by flow cytometry analysis of CD8 (+) cells from 43 ART-treated HIV-infected patients (HIV(+)) and ten Controls using markers of differentiation: CD27/CD28; maturation: CD27/CD45RA; senescence: killer cell lectin-like receptor G1 (KLRG1); and exhaustion: programmed death-1 (PD-1). Relationships between CD8 (+) T cell immunosenescence, exhaustion, and age-related processes were assessed using linear regressions.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26611787 PMCID: PMC4661963 DOI: 10.1186/s12865-015-0136-6
Source DB: PubMed Journal: BMC Immunol ISSN: 1471-2172 Impact factor: 3.615
Fig. 1Flowchart of the study participants. Abbreviations: HIV+: HIV-infected patients, KLRG1: killer cell lectin-like receptor G1, Lipo: lipodystrophic, Non-Lipo: non-lipodystrophic, PBMC: peripheral blood mononuclear cell, PD-1: programmed death-1
General characteristics of the study participants
| Controls | HIV+ | |||
|---|---|---|---|---|
|
|
| |||
| Median or n | IQR or % | Median or n | IQR or % | |
| Demography and lifestyle | ||||
| Age (years) | 48.1 | 41.9–62.3 | 49.8 | 43.3–55.2 |
| Smoking | 0 | 0 % |
| 32.6 % |
| Body composition | ||||
| Lipodystrophy | — | — | 14 | 32.6 % |
| BMI (kg/m2) | 25.4 | 24.7–28.6 | 25.1 | 23.0–27.7 |
| FMI (kg/m2) | 5.2 | 4.6–7.5 | 4.6 | 3.4–6.4 |
| VAT (cm2) | 111.6 | 93.5–157.5 | 150.8 | 115.0–212.2 |
|
| 6.4 | 6.2–6.8 | 6.1 | 5.7–6.6 |
| Metabolic parameters | ||||
| HOMA-IR | 0.5 | 0.5–1.3 |
| 0.6–2.4 |
| Metabolic syndrome | 1 | 10 % | 20 | 46.5 % |
| Biomarkers of inflammation | ||||
| IL-6 (pg/mL) | 1.1 | 0.7–2.4 | 1.6 | 1.1–2.6 |
| suPAR (ng/mL) | 1.8 | 1.5–2.1 |
| 1.8–2.8 |
| HIV- and immune-related parameters | ||||
| HIV duration (years) | — | — | 14 | 6.6–21.0 |
| ART duration (years) | — | — | 10.2 | 4.4–14.8 |
| Current PI treatment | — | — | 13 | 30.2 % |
| Current NRTI treatment | — | — | 43 | 100 % |
| Current NNRTI treatment | — | — | 28 | 65.1 % |
| Other current ART | — | — | 4 | 9.30 % |
| HIV RNA ≤20 copies/mL | — | — | 39 | 90.7 % |
| CD4 | 729 | 674–880 | 580 | 403–820 |
| CD8 | 373 | 281–440 |
| 618–1120 |
| CD4:CD8 ratio | 2.0 | 1.8–3.0 |
| 0.5–1.0 |
Continuous measures are listed as: median and interquartile range. Categorical variables are listed as: number of participants and percentage
Abbreviations: BMI body mass index, ART antiretroviral therapy, FMI fat mass index, HOMA-IR homeostatic model assessment of insulin resistance, IL-6 interleukin-6, IQR interquartile range, lLMI leg lean mass index, NRTI nucleoside reverse-transcriptase inhibitors, NNRTI non-nucleoside reverse-transcriptase inhibitor, PI protease inhibitor, suPAR soluble urokinase plasminogen activator receptor, VAT visceral adipose tissue
The bold values are statistically significant at * P < 0.05, ** P < 0.01, *** P < 0.001
Fig. 2CD8+ T cell maturation and differentiation in HIV+ and in Controls. a Proportions of CD8+ T cells in each maturation subset: naïve (TN), central memory (TCM), effector memory (TEM), or effector memory re-expressing CD45RA (TEMRA) b Proportions of CD8+ T cells in each differentiation subset: early differentiated (TED), intermediate differentiated (TID), late differentiated (TLD), or CD27−CD28+. HIV+ (N = 43) and Controls (N = 10). Medians are shown as horizontal bars. P-values were determined using unpaired Student’s t-test or Wilcoxon two-sample test
Fig. 3CD8+ T cell exhaustion and senescence in HIV+ and in Controls. a Proportions of PD-1+ cells in total CD8+ T cells and in CD8+ T cell subsets in HIV-infection and in Controls. HIV+ (N = 43) and Controls (N = 10). b Proportions of KLRG1+ cells in total CD8+ T cells and in CD8+ T cell subsets in HIV+ and in Controls. HIV+ (N = 30) and Controls (N = 9). Medians are shown as horizontal bars. P-values were determined using unpaired Student’s t-test or Wilcoxon two-sample test
Fig. 4Unadjusted and adjusted associations between Memory and CD28−CD8+ T cells and ageing parameters in HIV+. Age was adjusted for HIV-, ART-duration, and current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were adjusted for age, HIV-, ART-duration, and current ART. Estimates are shown as unit increase in the outcome per unit increase of the covariate. The dashed line marks an estimate change of 0 units. *P < 0.05. Abbreviations: HOMA-IR: homeostatic model assessment of insulin resistance; IL-6: interleukin-6; lLMI: leg lean mass index; suPAR: soluble urokinase plasminogen activator receptor; VAT: visceral adipose tissue
Fig. 5Unadjusted and adjusted associations between KLRG1+ and PD-1+CD8+ T cells and ageing parameters in HIV+. Age was adjusted for HIV-, ART-duration, and current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were adjusted for age, HIV-, ART-duration, and current ART. Parameters were transformed using log2(x). Estimates and 95 % CI are back transformed using (2β-1) × 100 and shown as percent change in the outcome per unit increase of the covariate. The dashed line marks an estimate change of 0 %. Abbreviations: HOMA-IR: homeostatic model assessment of insulin resistance; IL-6: interleukin-6; KLRG1: killer cell lectin-like receptor G1; lLMI: leg lean mass index; PD-1: programmed death-1; suPAR: soluble urokinase plasminogen activator receptor; VAT: visceral adipose tissue
Unadjusted and adjusted associations between KLRG1+CD8+ T cell groups and ageing parameters in HIV+
| Maturation - CD27/CD45RA | Differentiation - CD27/CD28 | |||||||
|---|---|---|---|---|---|---|---|---|
| % KLRG1+ TN a | % KLRG1+ Memorya | % KLRG1+CD28+a | % KLRG1+CD28− | |||||
| Estimate | 95 % CI | Estimate | 95 % CI | Estimate | 95 % CI | Estimate | 95 % CI | |
| Age (per year extra) | −0.84 | −4.32 – 2.77 | 1.12 | −2.19 – 4.53 | 1.54 | −1.73 – 4.93 | 0.05 | −0.81 – 0.92 |
| −0.16 | −4.22 – 4.07 | 0.32 | −3.53 – 4.32 | 0.49 | −3.16 – 4.28 | −0.24 | −1.24 – 0.76 | |
| IL-6 (per extra pg/mL) | −0.24 | −17.69 – 20.92 | −8.07 | −22.94 – 9.68 | 3.27 | −13.80 – 23.71 | −0.84 | −5.53 – 3.85 |
| −2.98 | −21.71 – 20.23 | −7.08 | −23.90 – 13.47 | 9.10 | −9.84 – 32.03 | 0.11 | −5.16 – 5.38 | |
| suPAR (per extra ng/mL) | −13.66 | −40.90 – 26.14 | −21.72 | −44.54 – 10.50 | −18.83 | −42.12 – 13.82 | −5.62 | −14.38 – 3.14 |
| −15.63 | −43.65 – 26.30 | −20.25 | −45.09 – 15.84 | −17.17 | −41.55 – 17.38 | −4.90 | −14.36 – 4.56 | |
| HOMA-IR (per extra 1-unit) | 16.39 | −17.36 – 63.93 | 18.91 | −13.42 – 63.30 | 27.27 | −6.34 – 72.93 | 6.02 | −1.96 – 14.01 |
| 35.74 | −9.23 – 103.01 | 22.91 | −16.71 – 81.38 | 27.45 | −10.90 – 82.29 | 6.98 | −2.65 – 16.16 | |
| Metabolic syndrome (vs. no metabolic syndrome) | 23.25 | −34.76 – 132.83 | 46.43 | −17.97 – 161.42 | 70.88 | −1.41 – 196.17 |
| 0.10 – 28.53 |
| 48.94 | −29.02 – 212.55 | 41.31 | −29.88 – 184.78 | 61.77 | −15.73 – 210.55 |
| 0.73 – 34.45 | |
| VAT (per extra cm2) | −0.10 | −0.55 – 0.35 | 0.28 | −0.12 – 0.70 |
| 0.06 – 0.84 | 0.10 | −0.00 – 0.20 |
| 0.14 | −0.54 – 0.82 | 0.28 | −0.34 – 0.90 |
| 0.07 – 1.16 |
| 0.01 – 0.31 | |
|
|
| 10.22 – 151.43 | 36.88 | −5.52 – 98.30 | 22.54 | −20.06 – 87.86 | 7.92 | −2.88 – 18.71 |
| 59.19 | −0.55 – 154.80 | 45.52 | −1.35 – 114.65 | 33.83 | −13.85 – 107.92 | 10.09 | −1.22 – 21.39 | |
Adjusted analyses are in grey. Age was adjusted for HIV-duration, ART-duration, and current ART; IL-6, suPAR, HOMA-IR, metabolic syndrome, VAT, and lLMI were adjusted for age, HIV-duration, ART-duration, and current ART
Abbreviations: HOMA-IR homeostatic model assessment of insulin resistance, IL-6 interleukin-6, KLRG1 killer cell lectin-like receptor G1, lLMI leg lean mass index, suPAR soluble urokinase plasminogen activator receptor, T naïve T cell, VAT visceral adipose tissue
The bold values are statistically significant at * P < 0.05
aParameters were transformed using log2(x). Estimates and confidence intervals are back transformed using (2β-1) × 100, and shown as percent change in the outcome per unit increase of the covariate